PURPOSE: To perform a reliable non-invasive detection of the fetal achondroplasia using maternal plasma. METHODS: We developed a quantitative fluorescent-polymerase chain reaction (QF-PCR) method suitable for detection of the FGFR3 mutation (G1138A) causing achondroplasia. This method was applied in a non-invasive detection of the fetal achondroplasia using circulating fetal-DNA (cf-DNA) in maternal plasma. Maternal plasmas were obtained at 27 weeks of gestational age from women carrying an achondroplasia fetus or a normal fetus. RESULTS: Two percent or less achondroplasia DNA was reliably detected by QF-PCR. In a woman carrying a normal fetus, analysis of cf-DNA showed only one peak of the wild-type G allele. In a woman expected an achondroplasia fetus, analysis of cf-DNA showed the two peaks of wild-type G allele and mutant-type A allele and accurately detected the fetal achondroplasia. CONCLUSIONS: The non-invasive method using maternal plasma and QF-PCR may be useful for diagnosis of the fetal achondroplasia.
PURPOSE: To perform a reliable non-invasive detection of the fetal achondroplasia using maternal plasma. METHODS: We developed a quantitative fluorescent-polymerase chain reaction (QF-PCR) method suitable for detection of the FGFR3 mutation (G1138A) causing achondroplasia. This method was applied in a non-invasive detection of the fetal achondroplasia using circulating fetal-DNA (cf-DNA) in maternal plasma. Maternal plasmas were obtained at 27 weeks of gestational age from women carrying an achondroplasia fetus or a normal fetus. RESULTS: Two percent or less achondroplasia DNA was reliably detected by QF-PCR. In a woman carrying a normal fetus, analysis of cf-DNA showed only one peak of the wild-type G allele. In a woman expected an achondroplasia fetus, analysis of cf-DNA showed the two peaks of wild-type G allele and mutant-type A allele and accurately detected the fetal achondroplasia. CONCLUSIONS: The non-invasive method using maternal plasma and QF-PCR may be useful for diagnosis of the fetal achondroplasia.
Authors: V Cirigliano; M Ejarque; M P Cañadas; E Lloveras; A Plaja; M M Perez; C Fuster; J Egozcue Journal: Mol Hum Reprod Date: 2001-10 Impact factor: 4.025
Authors: Rossa W K Chiu; Tze K Lau; Tse N Leung; Katherine C K Chow; David H K Chui; Y M Dennis Lo Journal: Lancet Date: 2002-09-28 Impact factor: 79.321
Authors: K C Allen Chan; Jun Zhang; Angela B Y Hui; Nathalie Wong; Tze K Lau; Tse N Leung; Kwok-Wai Lo; Dolly W S Huang; Y M Dennis Lo Journal: Clin Chem Date: 2004-01 Impact factor: 8.327
Authors: G A Bellus; T W Hefferon; R I Ortiz de Luna; J T Hecht; W A Horton; M Machado; I Kaitila; I McIntosh; C A Francomano Journal: Am J Hum Genet Date: 1995-02 Impact factor: 11.025
Authors: R Shiang; L M Thompson; Y Z Zhu; D M Church; T J Fielder; M Bocian; S T Winokur; J J Wasmuth Journal: Cell Date: 1994-07-29 Impact factor: 41.582
Authors: R J P Rijnders; R B Van Der Luijt; E D J Peters; J K Goeree; C E Van Der Schoot; J K Ploos Van Amstel; G C M L Christiaens Journal: Prenat Diagn Date: 2003-12-30 Impact factor: 3.050
Authors: Sara Perlado; Ana Bustamante-Aragonés; Marta Donas; Isabel Lorda-Sánchez; Javier Plaza; Marta Rodríguez de Alba Journal: PLoS One Date: 2016-04-14 Impact factor: 3.240